These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36316000)

  • 1. Sociodemographic and Clinical Factors Associated with Treatment Outcomes for Drug-resistant Tuberculosis.
    de Oliveira Jeronymo Neves AC; Gomes Dos Santos AP; de Medeiros RL; de Oliveira Jeronymo AJ; Coelho Neves G; de Almeida IN; Carvalho de Queiroz Mello F; Lineu Kritski A
    Am J Trop Med Hyg; 2022 Dec; 107(6):1295-1301. PubMed ID: 36316000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia.
    Woldeyohannes D; Assefa T; Aman R; Tekalegn Y; Hailemariam Z
    PLoS One; 2019; 14(10):e0224025. PubMed ID: 31665154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The differences in drug resistance between drug-resistant tuberculosis patients with and without diabetes mellitus in northeast China: a retrospective study.
    Pan Y; Yu Y; Yi Y; Dou X; Lu J; Zhou L
    BMC Infect Dis; 2023 Mar; 23(1):162. PubMed ID: 36922787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
    Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
    BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
    Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
    BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of multidrug-resistant tuberculosis in São Paulo-Brazil: a multilevel Bayesian analysis of factors associated with individual, community and access to health services.
    Arroyo LH; Yamamura M; Ramos ACV; Campoy LT; Crispim JA; Berra TZ; Alves LS; Alves YM; Dos Santos FL; Souza LLL; Bruce ATI; de Andrade HLP; Bollela VR; Krainski ET; Nunes C; Arcêncio RA
    Trop Med Int Health; 2020 Jul; 25(7):839-849. PubMed ID: 32358845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and factors associated with multidrug-resistant tuberculosis in South India.
    Shivekar SS; Kaliaperumal V; Brammacharry U; Sakkaravarthy A; Raj CKV; Alagappan C; Muthaiah M
    Sci Rep; 2020 Oct; 10(1):17552. PubMed ID: 33067551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015.
    Pradipta IS; Van't Boveneind-Vrubleuskaya N; Akkerman OW; Alffenaar JC; Hak E
    Antimicrob Resist Infect Control; 2019; 8():115. PubMed ID: 31338162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of tuberculosis patients in the integrated tuberculosis control model in Chongqing, China: a retrospective study.
    Zhang L; Xing W; Zhou J; Zhang R; Cheng Y; Li J; Wang G; Liu S; Li Y
    BMC Infect Dis; 2020 Aug; 20(1):576. PubMed ID: 32758169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.
    Tembo BP; Malangu NG
    BMC Infect Dis; 2019 Sep; 19(1):779. PubMed ID: 31492099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
    PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with loss to follow-up and death in cases of drug-resistant tuberculosis (DR-TB) treated at a reference center in Rio de Janeiro, Brazil.
    Viana PVS; Redner P; Ramos JP
    Cad Saude Publica; 2018 May; 34(5):e00048217. PubMed ID: 29768580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Analysis of Prevalence and Risk Factors of Rifampicin-Resistant Tuberculosis in Zhejiang, China.
    Liu Z; Zhang M; Wang J; Chen S; Wu B; Zhou L; Pan A; Wang W; Wang X
    Biomed Res Int; 2020; 2020():3159482. PubMed ID: 32104686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991-1993.
    Chum HJ; O'Brien RJ; Chonde TM; Graf P; Rieder HL
    AIDS; 1996 Mar; 10(3):299-309. PubMed ID: 8882670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013-2015: A retrospective cohort study.
    Chaves-Torres NM; Fadul S; Patiño J; Netto E
    PLoS One; 2021; 16(4):e0249565. PubMed ID: 33852619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and genetic determinant of drug-resistant tuberculosis among patients completing intensive phase of treatment in a Tertiary Referral Center in Nigeria.
    Mohammad AB; Iliyasu G; Habib AG
    Int J Mycobacteriol; 2017; 6(1):47-51. PubMed ID: 28317805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000-2016.
    Bhering M; Duarte R; Kritski A
    PLoS One; 2019; 14(11):e0218299. PubMed ID: 31747405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017.
    Glasauer S; Altmann D; Hauer B; Brodhun B; Haas W; Perumal N
    PLoS One; 2019; 14(6):e0217597. PubMed ID: 31188848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India.
    Isaakidis P; Das M; Kumar AM; Peskett C; Khetarpal M; Bamne A; Adsul B; Manglani M; Sachdeva KS; Parmar M; Kanchar A; Rewari BB; Deshpande A; Rodrigues C; Shetty A; Rebello L; Saranchuk P
    PLoS One; 2014; 9(10):e110461. PubMed ID: 25333696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.